Bayer’s Supreme Court Win Lifts the Legal Fog — but the Balance Sheet Still Hasn’t Cleared
Published on 06/27/2026 at 16:55 | Redaktion boerse-global.de
The US Supreme Court handed Bayer a landmark victory last week, ruling 7-2 that federal pesticide law preempts state-level claims over missing cancer warnings on glyphosate. The decision eviscerates the legal foundation of thousands of Roundup lawsuits and triggered a 23% rally in the stock, which closed Friday at €46.61 — within striking distance of its 52-week high near €50.
Yet for all the euphoria, the underlying financial picture remains strained. Bayer’s free cash flow swung to a negative €2.32 billion in the first quarter of 2026, worse than the €1.53 billion deficit a year earlier, as payments for PCB and glyphosate litigation drained liquidity. Net financial debt swelled to over €32.5 billion by the end of March. CFO Wolfgang Nickl has pencilled in roughly €5 billion in litigation outflows for the full year, leaving free cash flow in a range of minus €1.5 billion to minus €2.5 billion by December.
The key question for investors is when the legal relief will actually translate into lower cash burn. The Supreme Court’s ruling weakens the largest category of Roundup cases — those centered on warning labels — but Bayer is still pushing a $7.25 billion settlement framework for remaining claims. A Missouri court gave preliminary approval in March, and a final hearing is set for July 9. If the deal sticks, it removes a multi-billion-dollar overhang. If it collapses, a chunk of the legal reprieve evaporates.
Should investors sell immediately? Or is it worth buying Bayer?
On the operational front, there are bright spots that could offset the drag. The company’s experimental stroke-prevention drug Asundexian received accelerated review status from the US FDA and Chinese regulators in May, with the European Medicines Agency also evaluating its application. Successful approvals would make Bayer the first to market with an FXIa inhibitor, helping to fill the revenue hole left by Xarelto, whose sales fell by a third last year to $2.6 billion. Separately, the FDA approved Bayer’s MRI contrast agent Ambelvist in mid-June, adding to the pharma pipeline.
But the balance sheet remains the elephant in the room. Provisions for litigation stood at €9.6 billion at last count, and the $7.25 billion settlement framework will consume capital for some time. Analysts have responded cautiously to the court win: DZ Bank raised its fair value to €54, Jefferies lifted its target to €46, and UBS kept a Buy with a €52 target. Yet the stock has already overshot Jefferies’ new target, and the RSI of 80.6 screams overbought. The 14-day relative strength index at that level has historically preceded a sharp pullback; the share price is trading 22.9% above its 50-day moving average of €37.93.
The technical risk is amplified by the sheer speed of the move. With an annualised volatility of 57.8%, Bayer remains a high-octane name. Short-term profit-taking looks probable, and a consolidation toward the 200-day line at €36.59 would be healthy for the medium-term trend.
Looking ahead, two catalysts dominate the calendar. The Missouri hearing on July 9 will determine whether the $7.25 billion settlement stands. Then the second-quarter results must deliver hard evidence of a narrowing cash flow deficit. The management team under Bill Anderson is expected to unveil a detailed strategic update in the second half of 2026. If the cash flow numbers improve and the settlement holds, the stock has a clear path to retest the €50 high. If the legal process stumbles or the operating losses persist, the overbought RSI leaves ample room for a sharp correction.
Ad
Bayer Stock: New Analysis - 27 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
